Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Triple Negative Breast Cancer
Related studies linked through entity extraction aliases.
Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC
- Status
- COMPLETED
- Phase
- PHASE2
Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC
- Status
- UNKNOWN
- Phase
- PHASE2
CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
MicroRNA Profiles in Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
- Status
- TERMINATED
- Phase
- PHASE1
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study of PY314 in Subjects With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2